Related scientific articles (all)

Transfer of clinically relevant gene expression signatures in breast cancer: from Affymetrix microarray to Illumina RNA-Sequencing technology.

Authors : Fumagalli D, Blanchet-Cohen A, Brown D, Desmedt C, Gacquer D, Michiels S, Rothé F, Majjaj S, Salgado R, Larsimont D, Ignatiadis M, Maetens M, Piccart-Gebhart M, Detours V, Sotiriou C, Haibe-Kains B
Year : 2014
Journal : BMC Genomics
Volume : 15(1)
Pages : 1008

Deciphering clonality in aneuploid tumors using SNP array and sequencing data.

Authors : Lönnstedt IM, Caramia F, Li J, Fumagalli D, Salgado R, Rowan A, Salm M, Kanu N, Savas P, Horswell S, Gade S, Loibl S, Neven P, Sotiriou C, Swanton C, Loi S, Speed TP
Year : 2014
Journal : Genome Biol.
Volume : 15(9)
Pages : 470

Is the differentiation into molecular subtypes of breast cancer important for staging, local and systemic therapy, and follow up?

Authors : Sonnenblick A, Fumagalli D, Sotiriou C, Piccart-Gebhart M
Year : 2014
Journal : Cancer Treat Rev
Volume : 40(9)
Pages : 1089-95

PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer.

Authors : Loibl S, Von Minckwitz G, Schneeweiss A, Paepke S, Lehmann A, Rezai M, Zahm DM, Sinn P, Khandan F, Eidtmann H, Dohnal K, Heinrichs C, Huober J, Pfitzner B, Fasching PA, Andre F, Lindner JL, Sotiriou C, Dykgers A, Guo S, Gade S, Nekljudova V, Loi S, Untch M, Denkert C
Year : 2014
Journal : J. Clin. Oncol.
Volume : 32(29)
Pages : 3212-20

New Strategies in Breast Cancer: The Significance of Molecular Subtypes in Systemic Adjuvant Treatment for Small T1a,bN0M0 Tumors.

Authors : Sonnenblick A, Fumagalli D, Azim HA, Sotiriou C, Piccart-Gebhart M
Year : 2014
Journal : Clin Cancer Res
Volume : 20(24)
Pages : 6242-6

The AURORA initiative for metastatic breast cancer.

Authors : Zardavas D, Maetens M, Irrthum A, Goulioti T, Engelen K, Fumagalli D, Salgado R, Aftimos P, Saini KS, Sotiriou C, Campbell P, Dinh P, Von Minckwitz G, Gelber Rd, Dowsett M, Di Leo A, Cameron D, Baselga J, Gnant M, Goldhirsch A, Norton L, Piccart-Gebhart M
Year : 2014
Journal : Br J Cancer
Volume : 111(10)
Pages : 1881-7

Plasma circulating tumor DNA as an alternative to metastatic biopsies for mutational analysis in breast cancer.

Authors : Rothé F, Laes JF, Lambrechts D, Smeets D, Vincent D, Maetens M, Fumagalli D, Michiels S, Drisis S, Moerman C, Detiffe JP, Larsimont D, Awada A, Piccart-Gebhart M, Sotiriou C, Ignatiadis M
Year : 2014
Journal : Ann Oncol
Volume : 25(10)
Pages : 1959-65

Regulation of DNA Methylation Patterns by CK2-Mediated Phosphorylation of Dnmt3a.

Authors : Deplus R, Blanchon L, Rajavelu A, Boukaba A, Defrance M, Luciani J, Rothé F, Dedeurwaerder S, Denis H, Brinkman AB, Simmer F, Müller F, Bertin B, Berdasco M, Putmans P, Calonne E, Litchfield DW, de Launoit Y, Jurkowski TP, Stunnenberg HG, Bock C, Sotiriou C, Fraga MF, Esteller M, Jeltsch A, Fuks F
Year : 2014
Journal : Cell Rep
Volume : 8(3)
Pages : 743-753

Pertuzumab: new hope for patients with HER2-positive breast cancer.

Authors : Capelan M, Pugliano L, de Azambuja E, Bozovic I, Saini KS, Sotiriou C, Loi S, Piccart-Gebhart M
Year : 2013
Journal : Ann Oncol
Volume : 24(2)
Pages : 273-82

Genomic Grade Index (GGI): feasibility in routine practice and impact on treatment decisions in early breast cancer.

Authors : Metzger-Filho O, Catteau A, Michiels S, Buyse M, Ignatiadis M, Saini KS, de Azambuja E, Fasolo V, Naji S, Canon JL, Delrée P, Coibion M, Cusumano P, Jossa V, Kains JP, Larsimont D, Richard V, Faverly D, Cornez N, Vuylsteke P, Vanderschueren B, Peyro-Saint-Paul H, Piccart-Gebhart M, Sotiriou C
Year : 2013
Journal : PLoS One
Volume : 8(8)
Pages : e66848

Genomic grade adds prognostic value in invasive lobular carcinoma.

Authors : Metzger-Filho O, Michiels S, Bertucci F, Catteau A, Salgado R, Galant C, Fumagalli D, Singhal SK, Desmedt C, Ignatiadis M, Sandy H, Finetti P, Birnbaum D, Saini KS, Berlière M, Veys I, de Azambuja E, Bozovic I, Peyro-Saint-Paul H, Larsimont D, Piccart-Gebhart M, Sotiriou C
Year : 2013
Journal : Ann Oncol
Volume : 24(2)
Pages : 377-84

Proliferation and estrogen signaling can distinguish patients at risk for early versus late relapse among estrogen receptor positive breast cancers.

Authors : Bianchini G, Pusztai L, Karn T, Iwamoto T, Rody A, Kelly CM, Müller V, Schmidt M, Qi Y, Holtrich U, Becker S, Santarpia L, Fasolo A, Del Conte G, Zambetti M, Sotiriou C, Haibe-Kains B, Symmans WF, Gianni L
Year : 2013
Journal : Breast Cancer Res
Volume : 15(5)
Pages : R86

TOP2A protein by quantitative immunofluorescence as a predictor of response to epirubicin in the neoadjuvant treatment of breast cancer.

Authors : Moretti E, Desmedt C, Biagioni C, Regan MM, Oakman C, Larsimont D, Galardi F, Piccart-Gebhart M, Sotiriou C, Rimm DL, Di Leo A
Year : 2013
Journal : Future Oncol
Volume : 9(10)
Pages : 1477-87

Genomic grade adds prognostic value in invasive lobular carcinoma.

Authors : Metzger-Filho O, Michiels S, Bertucci F, Catteau A, Salgado R, Galant C, Fumagalli D, Singhal SK, Desmedt C, Ignatiadis M, Haussy S, Finetti P, Birnbaum D, Saini KS, Berlière M, Veys I, de Azambuja E, Bozovic I, Peyro-Saint-Paul H, Larsimont D, Piccart-Gebhart M, Sotiriou C
Year : 2013
Journal : Ann Oncol
Volume : 24
Pages : 377-384

Circulating tumor cells and response to neoadjuvant paclitaxel and HER2-targeted therapy: A sub-study from the NeoALTTO phase III trial.

Authors : Azim HA, Rothé F, Aura CM, Bavington M, Maetens M, Rouas G, Gebhart G, Gamez C, Eidtmann H, Baselga J, Piccart-Gebhart M, Ellis C, Vuylsteke P, Cure H, Domont J, Ferro A, Toral-Peña JC, de Azambuja E, Sotiriou C, Di Cosimo S, Ignatiadis M
Year : 2013
Journal : Breast
Volume : 22(6)
Pages : 1060-5

Phase I trial combining temozolomide plus lapatinib for the treatment of brain metastases in patients with HER2-positive metastatic breast cancer: the LAPTEM trial.

Authors : de Azambuja E, Zardavas D, Lemort M, Rossari J, Moulin C, Buttice A, Dhondt V, Lebrun F, Lalami Y, Cardoso F, Sotiriou C, Gil T, Devriendt D, Paesmans M, Piccart-Gebhart M, Awada A
Year : 2013
Journal : Ann Oncol
Volume : 24(12)
Pages : 2985-9

Somatic Mutation Profiling and Associations With Prognosis and Trastuzumab Benefit in Early Breast Cancer.

Authors : Loi S, Michiels S, Lambrechts D, Fumagalli D, Claes B, Kellokumpu-Lehtinen PL, Bono P, Kataja V, Piccart-Gebhart M, Joensuu H, Sotiriou C
Year : 2013
Journal : J. Natl. Cancer Inst.
Volume : 105(13)
Pages : 960-967

Luminal breast cancer: from biology to treatment.

Authors : Ignatiadis M, Sotiriou C
Year : 2013
Journal : Nat Rev Clin Oncol
Volume : 10(9)
Pages : 494-506

CD4+ follicular helper T cell infiltration predicts breast cancer survival.

Authors : Gu-Trantien C, Loi S, Garaud S, Equeter C, Libin M, de Wind A, Ravoet M, Le Buanec H, Sibille C, Manfouo-Foutsop G, Veys I, Haibe-Kains B, Singhal SK, Michiels S, Rothé F, Salgado R, Duvillier H, Ignatiadis M, Desmedt C, Bron D, Larsimont D, Piccart-Gebhart M, Sotiriou C, Willard-Gallo K
Year : 2013
Journal : J Clin Invest
Volume : 123(7)
Pages : 2873-92

Interactions between immunity, proliferation and molecular subtype in breast cancer prognosis.

Authors : Nagalla S, Chou JW, Willingham MC, Ruiz J, Vaughn JP, Dubey P, Lash TL, Hamilton-Dutoit SJ, Bergh J, Sotiriou C, Black MA, Miller LD
Year : 2013
Journal : Genome Biol.
Volume : 14(4)
Pages : R34